Literature DB >> 18166778

How we diagnose and treat WHO-defined systemic mastocytosis in adults.

Ayalew Tefferi, Srdan Verstovsek, Animesh Pardanani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18166778     DOI： 10.3324/haematol.12324

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  8 in total

1.  Advanced mast cell disease: an Italian Hematological Multicenter experience.

Authors:  Livio Pagano; Caterina Giovanna Valentini; Morena Caira; Michela Rondoni; Maria Teresa Van Lint; Anna Candoni; Bernardino Allione; Chiara Cattaneo; Laura Marbello; Cecilia Caramatti; Enrico Maria Pogliani; Emilio Iannitto; Fiorina Giona; Felicetto Ferrara; Rosangela Invernizzi; Rosa Fanci; Monia Lunghi; Luana Fianchi; Grazia Sanpaolo; Pietro Maria Stefani; Alessandro Pulsoni; Giovanni Martinelli; Giuseppe Leone; Pellegrino Musto
Journal:  Int J Hematol       Date:  2008-11-26       Impact factor: 2.490

Review 2.  Midostaurin: a magic bullet that blocks mast cell expansion and activation.

Authors:  P Valent; C Akin; K Hartmann; T I George; K Sotlar; B Peter; K V Gleixner; K Blatt; W R Sperr; P W Manley; O Hermine; H C Kluin-Nelemans; M Arock; H-P Horny; A Reiter; J Gotlib
Journal:  Ann Oncol       Date:  2017-10-01       Impact factor: 32.976

3.  Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis.

Authors:  Alfonso Quintás-Cardama; Matjaz Sever; Jorge Cortes; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2013-01-23

Review 4.  Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis.

Authors:  Alfonso Quintás-Cardama; Nitin Jain; Srdan Verstovsek
Journal:  Cancer       Date:  2011-06-20       Impact factor: 6.860

5.  Mastocytosis: a disease of the hematopoietic stem cell.

Authors:  Hans-Peter Horny; Karl Sotlar; Peter Valent; Karin Hartmann
Journal:  Dtsch Arztebl Int       Date:  2008-10-03       Impact factor: 5.594

Review 6.  [Chronic myeloid neoplasms. Diagnostic criteria and current therapeutic concepts].

Authors:  A H Schmitt-Graeff
Journal:  Pathologe       Date:  2010-02       Impact factor: 1.011

7.  Comprehensive genomic profiling identifies a novel TNKS2-PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy.

Authors:  Z R Chalmers; S M Ali; R S Ohgami; P V Campregher; G M Frampton; R Yelensky; J A Elvin; N A Palma; R Erlich; J-A Vergilio; J Chmielecki; J S Ross; P J Stephens; R Hermann; V A Miller; C R Miles
Journal:  Blood Cancer J       Date:  2015-02-06       Impact factor: 11.037

8.  Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth.

Authors:  B Peter; G E Winter; K Blatt; K L Bennett; G Stefanzl; U Rix; G Eisenwort; E Hadzijusufovic; M Gridling; C Dutreix; G Hoermann; J Schwaab; D Radia; J Roesel; P W Manley; A Reiter; G Superti-Furga; P Valent
Journal:  Leukemia       Date:  2015-09-09       Impact factor: 11.528
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.